Moxifloxacin is a broad-spectrum fourth-generation fluoroquinolone antibiotic. It is a bactericidal agent that inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication, transcription, repair, and recombination. It is particularly effective against Gram-positive, Gram-negative, and atypical respiratory pathogens. In India, it is a critical agent for managing community-acquired pneumonia, acute bacterial sinusitis, and other infections, but its use is restricted due to concerns about fluoroquinolone-associated adverse effects.
Adult: 400 mg orally or intravenously once every 24 hours. Duration: Acute Bacterial Sinusitis: 10 days; Acute Bacterial Exacerbation of Chronic Bronchitis: 5 days; Community-Acquired Pneumonia: 7-14 days; Skin Infections: 7 days.
Note: Oral tablet can be taken with or without food. Swallow whole with a full glass of water. Do not crush or chew. Maintain adequate hydration. IV infusion: 400 mg in 250 mL of compatible solution (e.g., 0.9% Sodium Chloride, 5% Dextrose) infused over 60 minutes. Avoid rapid infusion. Do not administer as IV bolus.
Moxifloxacin is a bactericidal antibiotic. Its primary mechanism involves inhibition of two essential bacterial type II topoisomerase enzymes: DNA gyrase (primarily in Gram-negative bacteria) and topoisomerase IV (primarily in Gram-positive bacteria).
Pregnancy: Pregnancy Category C (US FDA). Animal studies have shown fetal arthropathy. There are no adequate and well-controlled studies in pregnant women. Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. Generally avoided.
Driving: May cause dizziness, lightheadedness, or visual disturbances. Patients should be cautioned about operating machinery or driving until they are certain they are not affected.
| Antacids (Aluminum, Magnesium), Sucralfate, Multivitamins with Zinc/Iron | Markedly reduced absorption of moxifloxacin due to chelation. Plasma levels may become subtherapeutic. | Major |
| Other QT-prolonging drugs (e.g., Class IA/III antiarrhythmics, Erythromycin, Antipsychotics, Tricyclic Antidepressants) | Additive effect on QT prolongation, increasing risk of life-threatening arrhythmias like Torsades de Pointes. | Major |
| Corticosteroids (e.g., Prednisolone) | Increased risk of tendon rupture, especially in elderly. | Major |
| Oral Anticoagulants (Warfarin) | May enhance anticoagulant effect; monitor INR closely. | Moderate |
| Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) | May increase the risk of CNS stimulation and seizures. | Moderate |
| Anti-diabetic agents (Insulin, Sulfonylureas like Glimepiride) | May potentiate hypoglycemic effect, leading to severe hypoglycemia. | Major |
| Theophylline | Limited interaction with moxifloxacin, but monitor for theophylline toxicity as a class precaution. | Moderate |